Isradipine detailed information

Isradipine detailed information

Clinical data
ATC code	C08CA03 (WHO)
Pharmacokinetic data
Protein binding	95%
Elimination half-life	8 hours
Identifiers
IUPAC name methyl propan-2-yl 2,6-dimethyl-4- (8-oxa-7,9-diazabicyclo[4.3.0] nona- 2,4,6,9- tetraen- 5-yl)- 1,4-dihydropyridine- 3,5-dicarboxylate
CAS Number	75695-93-1
PubChem CID	3784
DrugBank	APRD00298
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H21N3O5
Molar mass	371.387 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. More recent research suggests that isradipine may have potential uses for treating Parkinson's disease (Chan et al, 2007).

Further reading

• Hattori T, Wang P (2006). "Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts". Eur J Med Res. 11 (3): 93–6. PMID 16751108.
• Ganz M, Mokabberi R, Sica D (2005). "Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study". J Clin Hypertens (Greenwich). 7 (4 Suppl 1): 27–31. PMID 15858400.CS1 maint: Multiple names: authors list (link)
• Johnson B, Roache J, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y (2005). "Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects". Int J Neuropsychopharmacol. 8 (2): 203–13. PMID 15850499.CS1 maint: Multiple names: authors list (link)
• Fletcher H, Roberts G, Mullings A, Forrester T (1999). "An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia". J Obstet Gynaecol. 19 (3): 235–8. PMID 15512286.CS1 maint: Multiple names: authors list (link)

• C. Savio Chan, Jaime N. Guzman, Ema Ilijic, Jeff N. Mercer, Caroline Rick, Tatiana Tkatch, Gloria E. Meredith, D. James Surmeier (2007) Rejuvenation protects neurons in mouse models of Parkinson's disease. Nature. Nature advance online publication 10 June 2007 | doi:10.1038/nature05865

External links

• Template:MedlinePlusDrugInfo
• Template:DiseasesDB
• Drug offers hope for Parkinson's - BBC News, 11 June 2007.

Template:WikiDoc Sources